Table of Contents The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis TATA India PHARMA & Healthcare Fund - G
Scheme Objective
CAGR return of 6.5% since its launch. Return for 2019 was 5.5% , 2018 was -2.6% and 2017 was 4.7% . NAV as on 20 Oct 20 ₹13.5461 ↓ -0.01 (-0.10 %) Net Assets (AUM) as on 30 Sep 2020 ₹337 Cr. Launch Date 28 Dec 2015 Category Equity - Sectoral Rating Type Open Ended Fund Risk High AMC Tata Asset Management Limited Alpha Ratio 9.46 Expense Ratio 2.61 % Sharpe Ratio 1.676 Information Ratio 0.82 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 20 Oct 20 Duration Returns 1 Month -3.2% 3 Month 17.6% 6 Month 26.7% 1 Year 52.6% 3 Year 16.6% 5 Year 10 Year 15 Year Since launch 6.5% Historical Annual Returns
Year Returns 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% 2015 2014 2013 2012 2011 Growth of 10k Over Years
Date Value 30 Sep 16 ₹9,501 30 Sep 17 ₹8,151 30 Sep 18 ₹9,101 30 Sep 19 ₹8,790 30 Sep 20 ₹13,560 
Asset Allocation
Asset Class Value Cash 3.44% Equity 96.56% 
Sector Allocation
Sector Value Health Care 96.56% 
Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | 500124Drug Manufacturers - Specialty & Generic 15% ₹52 Cr 100,300
↓ -14,000 Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMADrug Manufacturers - Specialty & Generic 10% ₹35 Cr 690,100
↓ -180,000 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087Drug Manufacturers - General 9% ₹32 Cr 410,000
↑ 42,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 8% ₹28 Cr 92,500
↓ -10,000 Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 16 | 524494Drug Manufacturers - Specialty & Generic 7% ₹24 Cr 109,500
↑ 14,500 Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 29 Feb 20 | NHMedical Care Facilities 7% ₹22 Cr 626,720
↑ 200,000 Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 500257Drug Manufacturers - Specialty & Generic 6% ₹20 Cr 203,000
↑ 25,000 Laurus Labs Ltd (Healthcare)
Equity, Since 31 Jul 20 | 540222Drug Manufacturers - Specialty & Generic 5% ₹16 Cr 560,000
↑ 245,000 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Jul 18 | 500126Drug Manufacturers - Specialty & Generic 4% ₹13 Cr 26,000 Indoco Remedies Ltd (Healthcare)
Equity, Since 30 Jun 20 | 532612Drug Manufacturers - Specialty & Generic 3% ₹11 Cr 445,000
↑ 265,000
Talk to our investment specialistFund Managers
Name Since Tenure Rahul Singh 20 Apr 20 0.45 Yr. Meeta Shetty 20 Apr 20 0.45 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
Computer Age Management Services Ltd Address New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam FAX 91-44-28283610 Email enq_L@camsonline.com Administrator Companies
Company Address Tata Mutual Fund 1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051 Auditors
Company Address Deloitte Haskins & Sells 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli M/s BSR & Co. KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year TATA India Pharma & Healthcare Fund
Normal Dividend, Reinvestment ₹13.5461
↓ -0.01 26.65 % 52.63 % 16.61 % - TATA India Pharma & Healthcare Fund
Normal Dividend, Payout ₹13.5461
↓ -0.01 26.65 % 52.63 % 16.61 % - TATA India Pharma & Healthcare Fund
Growth ₹13.5461
↓ -0.01 26.65 % 52.63 % 16.61 % - Data as on 20 Oct 20
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2020 Shepard Technologies Private Limited. All Rights Reserved